<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434549</url>
  </required_header>
  <id_info>
    <org_study_id>BATCP</org_study_id>
    <nct_id>NCT02434549</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial</brief_title>
  <acronym>BATCP</acronym>
  <official_title>Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristina Tedroff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blinded, placebo-controlled study is to test if treatment with
      Botulinum toxin-A is effective in reducing chronic muscle-related pain in adults with spastic
      cerebral palsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders derived as reduction of intensity of pain of ≥2 points on the Numerical Rating Scale (NRS) at Visit 3 (six weeks after treatment) compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of other analgesic treatment</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Categories of change in the use of analgesic treatments, derived as Increase, No change, or Decrease at Visit 3 (six weeks after treatment), compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders derived as a reduction in mean interference score of ≥1 on the Brief Pain Inventory (BPI-SF) at Visit 3 (six weeks after treatment) compared to baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HRQoL (Health-Related Quality of Life)</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Mean change at Visit 3 (six weeks after treatment) compared to baseline in the Short Form 36 v2 Health-related Quality of Life questionnaire (SF-36v2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders at Visit 3 (six weeks after treatment) in the Global Impression of Change Scale (PGIC) derived as at least &quot;Minimally improved&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders at Visit 3 (six weeks after treatment) in the Fatigue Severity Scale (FSS) derived as a reduction in mean score of ≥1 point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Spasticity</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders at Visit 3 (six weeks after treatment) derived as achieving reduction of spasticity of &gt;1 scale steps on the Modified Ashworth Scale (MAS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Range of Motion</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Proportion of responders at Visit 3 (six weeks after treatment) derived as improvement in passive joint range of motion (ROM) ≥ 10 degrees.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Six weeks after treatment</time_frame>
    <description>Frequency of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pain</condition>
  <condition>Cerebral Palsy, Spastic</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin-A (Dysport®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport®</intervention_name>
    <description>Intramuscular injections in spastic muscle with regional muscle-related pain</description>
    <arm_group_label>Botulinum toxin-A (Dysport®)</arm_group_label>
    <other_name>AbobotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intramuscular injections in spastic muscle with regional muscle-related pain</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>0.9 % NaCl</other_name>
    <other_name>Physiological saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Spastic Cerebral Palsy.

          -  Chronic pain, related to spastic muscle. Chronic pain defined as: 1)Recurring regional
             pain for at least three months AND 2)Pain intensity on average for the last 24 hours
             ≥3 on Numerical Rating Scale.

          -  Signed Informed consent.

        Exclusion Criteria:

          -  Allergy/hypersensitivity to Dysport® or any of its components.

          -  Pregnancy.

          -  Women who breastfeed their children.

          -  Treatment with Botulinum toxin-A within the last five months.

          -  If there has been dose changes in any muscle-tone altering medication within two weeks
             of Visit 1.

          -  A clear degenerative cause behind the pain as elucidated by the clinical examination
             (e.g. history of osteoarthritis).

          -  Intellectual disability and/or communication impairment that disable the individual
             from answering the questionnaires and giving informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Tedroff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Women's and Children's Health, Karolinska Institutet. Senior Consultant Physician, Astrid Lindgren's Children's Hospital, Stockholm, Sweden.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan NO Jacobson, MD</last_name>
    <phone>+46851778074</phone>
    <email>dan.jacobson@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Tedroff, MD, PhD</last_name>
    <phone>+46851777374</phone>
    <email>kristina.tedroff@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Rehabilitation Medicine at Danderyd Hospital AB</name>
      <address>
        <city>Danderyd</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjell Kullander, MD</last_name>
      <phone>+46812355961</phone>
      <email>kjell.kullander@ds.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren's Children's Hospital at Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan NO Jacobson, MD</last_name>
      <phone>+46851778074</phone>
      <email>dan.jacobson@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Tedroff</investigator_full_name>
    <investigator_title>MD, PhD. Associate Professor. Senior Consultant Physician.</investigator_title>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Placebo Controlled</keyword>
  <keyword>Double Blinded</keyword>
  <keyword>Botulinum Toxin Type A</keyword>
  <keyword>Adults</keyword>
  <keyword>Pain</keyword>
  <keyword>Spasticity</keyword>
  <keyword>Cerebral Palsy, Spastic</keyword>
  <keyword>Dysport</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

